Company Overview - Genmab A/S is an international biotechnology company focused on improving the lives of patients through innovative antibody therapeutics [2] - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with a presence in North America, Europe, and Asia Pacific [3] Upcoming Events - Members of Genmab's Executive Committee will participate in investor conferences in March 2026, including: - TD Cowen 46 Annual Healthcare Conference in Boston on March 3, 2026, at 9:10 AM EST - Leerink Global Healthcare Conference in Miami on March 10, 2026, at 8:40 AM EDT - Barclays 28 Annual Global Healthcare Conference in Miami on March 11, 2026, at 1:30 PM EDT [6] Strategic Vision - By 2030, Genmab aims to transform the lives of individuals with cancer and other serious diseases through its proprietary pipeline of next-generation antibody medicines, referred to as "knock-your-socks-off" (KYSO) antibody medicines [2]

Genmab (NASDAQ:GMAB) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 17, Genmab reported that its total revenue grew by 19% in 2025 to a total $3.7 billion. This growth was fueled by a 54% surge in sales of its proprietary medicines, most notably Abkinley, which generated $468 million, which was a 67% year-over-year increase. The company also benefited from the continued success of its royalty portfolio, particularly Darzalex, which is projected to reach net sales of up to ...

Group 1 - The health care sector has identified oversold stocks, presenting potential buying opportunities for undervalued companies [1] - The Relative Strength Index (RSI) is a momentum indicator used to assess stock performance, with a value below 30 indicating that a stock is typically considered oversold [1] - A list of major oversold stocks in the health care sector includes companies with an RSI near or below 30 [2] Group 2 - Schrodinger Inc (NASDAQ:SDGR) has an RSI value of 29.9, indicating it is near the oversold threshold [3] - Schrodinger's stock has decreased approximately 28% over the past month, reaching a 52-week low of $11.15 [3] - On February 18, Schrodinger reported inducement grants under Nasdaq Listing Rule 5635(c)(4), and its shares rose 1.6% to close at $11.81 [3]

Exhibit 99.1 Genmab Announces Initiation of Share Buy-Back Program Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to honor our commitments under the Restricted Stock Unit program. The share buy- back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No. 596/2014 ('MAR') and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the "Safe Harbour ...

Financial Data and Key Metrics Changes - Total revenue increased by 19% to $3.7 billion in 2025, driven by strong execution across the royalty portfolio and commercialized medicines [25][26] - Operating profit expanded to $1.26 billion, reflecting strong execution and increasing operating leverage as the business scales [26][30] - Sales of proprietary medicines totaled $632 million, up 54% year-over-year, accounting for approximately 28% of total revenue growth [16][25] Business Line Data and Key Metrics Changes - Epkinly achieved $468 million in sales for 2025, representing a 67% year-over-year increase, driven by its dual indication in diffuse large B-cell lymphoma and follicular lymphoma [17][19] - Tivdak generated $164 million in sales, a 26% year-over-year increase, maintaining market leadership in recurrent or metastatic cervical cancer [20][21] Market Data and Key Metrics Changes - Epkinly closed 2025 with regulatory approvals in over 65 countries, nearly all featuring the dual indication [17] - The U.S. market saw increased uptake for Epkinly, particularly in community settings, with a majority of health systems ordering from multiple sites [18] Company Strategy and Development Direction - The company aims to accelerate the development of its late-stage pipeline and maximize the potential of its commercialized medicines, with a focus on sustainable growth into the 2030s [5][6] - The acquisition of Merus is expected to enhance the late-stage portfolio with petosemtamab, providing multiple value-creating catalysts in 2026 and beyond [8][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute on key data readouts in 2026 and subsequent high-impact launches in 2027, emphasizing a disciplined approach to capital allocation [31] - The company anticipates continued momentum in Epkinly and its royalty portfolio, with a revenue growth guidance of 14% for 2026 [27][30] Other Important Information - The company has five combined breakthrough therapy designations for its late-stage programs, which have multi-billion dollar potential [9] - The company is committed to deleveraging, targeting gross leverage below 3x by the end of 2027 [30] Q&A Session Summary Question: Next steps for Epkinly following EPCORE DLBCL-1 study results? - Management confirmed that the study showed positive progression-free survival but missed overall survival, and discussions with regulatory agencies are ongoing regarding the next steps [34][36] Question: Update on outpatient data for Epkinly? - Management indicated that the outpatient study is crucial for modifying the label and facilitating administration in the community [43][46] Question: Expectations for Rina-S pivotal phase two readout? - Management stated that the study is designed to support accelerated approval based on overall response rate and duration of response [51][54] Question: Expectations for EPCORE DLBCL 4 trial? - Management expressed optimism that the trial will lead to registration in second-line and third-line settings, differentiating it from other studies [58][60] Question: Thoughts on pembro approval in PROC and implications for Rina-S? - Management acknowledged the approval as a good option for patients but believes Rina-S can be more transformative for a broader population [62][64] Question: Confirmation on interim results for Epkinly frontline DLBCL trial? - Management reiterated that the readout for the study is expected to happen in 2026 [55][68]

Genmab (NasdaqGS:GMAB) Q4 2025 Earnings call February 17, 2026 12:00 PM ET Company ParticipantsAnthony Pagano - CFOBenjamin Jackson - VP of Equity ResearchBrad Bailey - CCOJames Gordon - Director and Head of European Pharma and Biotech & Life Sciences Equity ResearchJan van de Winkel - CEOJudith Klimovsky - Chief Development OfficerMatthew Phipps - Group Head–BiotechnologyTahamtan Ahmadi - CMOVictor Floc'h - Equity Research of PharmaceuticalsXian Deng - Executive Director and Pharma and Biotech Equity Resea ...

Financial Data and Key Metrics Changes - Total revenue increased by 19% to $3.7 billion in 2025, driven by strong execution across the royalty portfolio and commercialized medicines [24][25] - Operating profit expanded to $1.26 billion, reflecting strong execution and increasing operating leverage as the business scales [25][27] - Sales of proprietary medicines totaled $632 million, up 54% year over year, accounting for approximately 28% of total revenue growth [14][24] Business Line Data and Key Metrics Changes - Epkinly achieved $468 million in sales for the year, representing a 67% year-over-year increase, driven by its dual indication in diffuse large B-cell lymphoma and follicular lymphoma [15][24] - Tivdak generated $164 million in sales, representing a 26% year-over-year increase, maintaining market leadership in recurrent or metastatic cervical cancer [19][20] Market Data and Key Metrics Changes - Epkinly closed 2025 with regulatory approvals in more than 65 countries, nearly all featuring the dual indication [15] - The U.S. market saw increased uptake for Epkinly, particularly following its approval in second-line follicular lymphoma [17][18] - Tivdak's launch in Germany showed strong uptake, with positive physician feedback [20] Company Strategy and Development Direction - The company aims to accelerate the development of its late-stage pipeline and maximize the potential of its commercialized medicines [5][24] - The acquisition of Merus is expected to enhance the late-stage portfolio with petosemtamab, contributing to sustainable growth [6][25] - The focus for 2026 includes advancing proprietary portfolio impact, expanding market footprint, and preparing for multiple product launches [22][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute on key data readouts in 2026 and subsequent high-impact launches in 2027 [29] - The company anticipates continued revenue growth driven by Epkinly and its royalty portfolio, with a guidance of 14% total revenue growth for 2026 [26][28] - Management highlighted the importance of maintaining substantial profitability while investing in growth opportunities [27][28] Other Important Information - The company has five combined breakthrough therapy designations for its late-stage programs, indicating multi-billion dollar potential [7] - The anticipated data readouts in 2026 are expected to set the stage for multiple important product launches and line extensions in 2027 [8][10] Q&A Session Summary Question: Next steps for Epkinly following EPCORE DLBCL-1 study results - Management confirmed that the study showed positive progression-free survival but missed overall survival, with ongoing discussions with regulatory agencies about the data [31][33] Question: Update on outpatient data for Epkinly - Management indicated that the outpatient study is crucial for modifying the label and facilitating administration in the community [40][42] Question: Expectations for Rina-S pivotal phase two readout - Management stated that the study is designed to support accelerated approval based on overall response rate and duration of response [47][49] Question: Expectations for EPCORE DLBCL-4 trial outcomes - Management expressed optimism that the trial will lead to registration in second-line and third-line settings, differentiating it from other studies [53][55] Question: Thoughts on pembro approval in PROC and implications for Rina-S - Management acknowledged the approval as a good option for patients but believes Rina-S can be more transformative for a broader population [57][59] Question: Clarification on phase 3 for petosemtamab - Management confirmed that the phase 3 studies have dual endpoints of overall response rate and overall survival, which are standard in areas of unmet medical need [75]

Year End Results © Genmab 2024 Forward looking statement This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and object ...

Revenue Sources and Financial Risks - The majority of the company's revenue, 66%, in 2025 came from royalties on sales of DARZALEX, which is expected to continue to be a significant revenue source in the near term [39]. - The company's patents covering daratumumab will start to expire in the late 2020s, with US patent rights expiring in 2029, which may lead to a material decline in royalty revenues [44]. - The company may need to raise additional capital for future acquisitions or collaborations, which could be impacted by global economic conditions and market volatility [52]. - The company faces intense competition in the multiple myeloma therapy market, which could affect DARZALEX sales and overall revenue [45]. - The pricing of the company's products will depend on competitors' pricing strategies, which could negatively affect revenue from sales and royalties [117]. - The company may face challenges from lower-priced imports of its products, which could reduce revenues and lower sales margins [118]. - The company anticipates challenges from international reference pricing initiatives, including Most-Favored-Nation pricing, which could further pressure drug prices [169]. - The company may face significant liability if promotional practices do not comply with FDA regulations, potentially leading to penalties and reputational damage [163]. Growth and Development - The company has grown from 548 employees in 2019 to 3,029 by the end of 2025, reflecting rapid growth that requires careful management [50]. - The number of active industry-sponsored clinical trials for Genmab proprietary products increased from 12 in 2019 to 30 by the end of 2025, including nine Phase III trials [50]. - Future product launches may be delayed or impaired due to various factors, including supply constraints and regulatory approvals [47]. - The product pipeline includes five proprietary products and candidates in various stages of clinical development, with ongoing trials for multiple candidates from collaboration partners [87]. - The company has not advanced any product candidates through late-stage clinical development, which may require continued reliance on third-party contracts for development [91]. - The ongoing clinical development and commercialization of petosemtamab may not meet expected timelines or revenue potential, impacting overall business performance [224]. Regulatory and Compliance Challenges - Regulatory compliance is critical, as failure to meet ongoing requirements could adversely affect the company's ability to commercialize products and generate revenue [166]. - The company must navigate a rapidly evolving regulatory landscape, which could delay or prevent the approval of its products and impact financial results [167]. - The approval process for marketing drugs varies by jurisdiction, and approval in one region does not guarantee approval in others [105]. - The FDA may not accept data from trials conducted outside the US, potentially requiring additional costly trials for regulatory approval [100]. - Enhanced scrutiny of patient assistance programs may lead to legal challenges, potentially resulting in fines or sanctions that could disrupt business operations [183]. Intellectual Property and Legal Risks - The company’s ability to compete may decline if it cannot adequately protect its intellectual property rights or if government regulations negatively impact pricing and reimbursement [40]. - The company relies on proprietary technology licensed from third parties, which is critical for the development and commercialization of its products [135]. - The company may incur significant costs and time in litigation to protect its intellectual property rights, which could divert management's attention from core business operations [141]. - The company may be subject to claims that its products infringe third-party intellectual property rights, leading to potential litigation and licensing costs [145]. - The company faces challenges in enforcing patents in certain countries, particularly in developing regions, which may limit the benefits of patent protection [152]. Acquisition and Integration Risks - The acquisition of Merus may not yield the anticipated benefits, which could adversely affect the company's financial condition and results of operations [215]. - The integration of Merus' business may require greater resources and investments than originally anticipated, potentially leading to unknown liabilities [215]. - Potential difficulties in combining the businesses include the failure to integrate internal systems and controls effectively [216]. - Genmab's acquisition of Merus hinges on the successful clinical development, regulatory approval, and commercialization of petosemtamab, with no guarantee of achieving anticipated benefits [219]. Financial Condition and Debt - Substantial indebtedness may negatively impact Genmab's financial condition and limit financing options, requiring a significant portion of cash flow for debt service [225]. - The restrictive covenants in the company's debt agreements may hinder operational flexibility and limit strategic business pursuits [227]. - The company may struggle to obtain additional financing for working capital or acquisitions due to its high debt leverage [229]. - Cash flow dedicated to debt service payments could reduce available funds for capital expenditures and other corporate purposes [229]. - The company may face competitive disadvantages and increased vulnerability to economic downturns due to its indebtedness [229].

Core Insights - Genmab A/S published its Annual Report for 2025, highlighting significant business progress, financial performance, and outlook for 2026 [1] Business Progress - Epcoritamab (EPKINLY®) received FDA approval for earlier lines of therapy in follicular lymphoma, based on successful Phase 3 EPCORE® FL-1 trial results [6] - Acquisition of Merus N.V. adds a late-stage breakthrough therapy asset, petosemtamab, enhancing growth opportunities [6] - Tivdak® was approved in Europe and Japan for recurrent or metastatic cervical cancer, marking Genmab's first independent product launch [6] - Rina-S® expanded its Phase 3 development into endometrial cancer and platinum-sensitive ovarian cancer, receiving Breakthrough Therapy Designation from the FDA [6] - Continued development of organizational infrastructure with over 300 new hires [6] Financial Performance - Net sales of DARZALEX® reached $14,351 million in 2025, a 23% increase from $11,670 million in 2024 [6] - Global net sales of EPKINLY/TEPKINLY were $468 million in 2025, up 67% from $281 million in 2024, driven by growth in diffuse large B-cell lymphoma and follicular lymphoma [6] - Genmab's total revenue for 2025 was $3,720 million, a 19% increase from $3,121 million in 2024, primarily due to higher royalties from DARZALEX and Kesimpta [6] 2026 Outlook - Genmab projects 2026 revenue between $4,065 million and $4,395 million, with a midpoint guidance of $4,230 million [7] - Expected royalty revenue for 2026 is projected to be between $3,440 million and $3,685 million, with a midpoint of $3,563 million [7] - Anticipated operating expenses for 2026 are expected to range from $2,710 million to $2,910 million, reflecting investments in late-stage programs [13] - Projected operating profit for 2026 is estimated to be between $900 million and $1,400 million [14]